![]() The FDA warned that patients need to be very careful and cautious about products that are commercially available on Amazon or over the counter or through mail order websites that have not actually proven efficacy to the FDA. Because of the lack of consistency across manufacturers, both in the country or manufacturers in Canada, the FDA was warning providers and patients that there is no FDA-approved option yet. Miranti: In early June of 2023, the FDA came out with a pretty strongly worded consumer warning against using compounded cantharidin. We really want all dermatology providers across the country to have a consistent product that's reliable, readily available, and easy to use.ĭermatology Times: Why is compounded cantharidin not the best treatment selection for molluscum? Sometimes patients will receive a larger bolus of medication, sometimes certain lesions are missed. ![]() Unfortunately, there's not always consistency. For those of us who have been treating patients for years with cantharidin-or, as we call it “beetle juice”-we have been grabbing our little brown bottle from the cabinet and treating our patients. We've been using compounded cantharidin in our little brown bottle. ![]() ![]() So even though it's been a theorized medication, there was never an FDA-approved option for cantharidin. It was originally introduced to start to treat molluscum, even very early on, but it was pulled from the market in the 1960s because of lack of efficacy data submitted to the FDA. Cantharidin is actually a product that has been around since the 1950s. Sometimes the products that you get are not the same as the lot that you ordered last month, even if you're ordering from the exact same manufacturer. The problem is not all compounds are created equal there's a lot of variability, there's a lot of variations between compounding companies. Many of us were actually using compounded cantharidin, which in theory is a great option. Miranti: Previously, the standard of care in our pediatric patient population was a little bit all over the place because we had no specific guidelines. Because up until now, we’ve had no consistency.ĭermatology Times: What has been the previous standard of care for treating molluscum lesions in pediatric patients? This will truly start to help those providers that see molluscum, and there are a lot of us out there, gain consistency and our treatments. There is a purple-stained dye that is contained in the medication combination as well, that allows us to see the precise application location, so we know exactly what bumps have been treated and what bumps have not. We can very specifically treat the individual raised bumps. Until now, we finally have our very first FDA-approved product, Ycanth, which was known as VP-102, which is a drug-device combination product that applies a very small, precise amount of cantharidin and a surgical dye and is applied in-office to the patient's lesions. As of very recently, we have never had an FDA-approved treatment option for this very persistent, very stubborn skin condition. Miranti: Molluscum contagiosum is a very common associated viral condition that affects 6 million Americans, the majority of those being children, teens, and young adults. Dermatology Times® spoke with Miranti to discuss VP-102's approval and how previously, there have not been ideal standards of care.ĭermatology Times: Can you please explain the significance of VP-102 as a drug-device that precisely applies cantharidin 0.7% and the surgical dye, gentian? Shanna Miranti, MPAS, PA-C, a board-certified physician assistant at Riverchase Dermatology in Naples, Florida, specializes in adult and pediatric dermatology and treats molluscum contagiosum frequently at her practice. With VP-102, providers can apply a precise amount of cantharidin 0.7% to each individual molluscum lesion, while also marking each treated lesion with a violet dye to further prevent missed lesions or duplicate dosing. Molluscum contagiosum most commonly affects pediatric patients, beginning around aged 6 years. ![]() Providers have been eagerly awaiting the approval of VP-102, as molluscum contagiosum accounts for approximately 1% of all diagnosed skin conditions and is one of the 50 most common skin conditions. VP-102 is the first FDA-approved drug for the treatment of molluscum contagiosum and offers dermatology providers and patients a precise in-office treatment. VP-102 is a drug-device combination that contains a GMP–controlled formulation of cantharidin 0.7% w/v and gentian, a surgical dye meant to clearly mark treated lesions. Verrica Pharmaceutical’s VP-102 (Ycanth) was approved today by the US Food and Drug Administration (FDA) for the treatment of molluscum contagiosum. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |